Organon & Co. (BMV:OGN)
Mexico · Delayed Price · Currency is MXN | Market Cap | 60.95B +28.1% |
| Revenue (ttm) | 111.10B -2.1% |
| Net Income | 4.43B -67.2% |
| EPS | 16.99 -67.2% |
| Shares Out | n/a |
| PE Ratio | 13.74 |
| Forward PE | 3.96 |
| Dividend | 1.43 (0.62%) |
| Ex-Dividend Date | May 11, 2026 |
| Volume | n/a |
| Open | 230.00 |
| Previous Close | 231.82 |
| Day's Range | 229.00 - 230.00 |
| 52-Week Range | 106.15 - 245.00 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 6, 2026 |
About Organon & Co.
Organon & Co. develops and delivers women health solutions through prescription therapies and medical devices in the United States, Europe, Canada, Japan, rest of the Asia Pacific, China, Latin America, the Middle East, Russia, Africa, and internationally. The company's women’s health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, Marvelon, and Mercilon to prevent pregnancy; Follistim AQ, which is used to promote develo... [Read more]
Financial Performance
In 2025, Organon & Co.'s revenue was $6.22 billion, a decrease of -2.92% compared to the previous year's $6.40 billion. Earnings were $187.00 million, a decrease of -78.36%.
Financial numbers in USD Financial StatementsNews
Organon completes agreement to license MIUDELLA hormone-free IUD
Organon (OGN) announced the completion of a global licensing agreement with Sebela Pharmaceuticals, granting Organon exclusive rights to MIUDELLA, a hormone-free, copper intrauterine device. Approved ...
Organon Completes Agreement to License MIUDELLA®, Sebela Pharmaceuticals' Hormone-Free Intrauterine Device
JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon completes agreement to license MIUDELLA®, Sebela's hormone-free IUD, expanding its long-acting reversible contraception portfolio.
Organon and Samsung Bioepis expand commercialization agreement for Pyzchiva
Samsung Bioepis and Organon (OGN), a global healthcare company with expertise in biosimilars, announced the expansion of their development and commercialization agreement, whereby Organon will obtain ...
Organon and Samsung Bioepis Expand Agreement to Commercialize PYZCHIVA® (ustekinumab), a Biosimilar Referencing STELARA® (ustekinumab) in Canada
INCHEON, South Korea & KIRKLAND, Quebec--(BUSINESS WIRE)--Organon and Samsung Bioepis expand agreement to commercialize PYZCHIVA® (ustekinumab), a biosimilar referencing STELARA® (ustekinumab) in Cana...
Organon & Co. Proxy statement: Proxy filing
Organon & Co. filed a proxy statement on June 17, 2026, providing details for shareholder voting and corporate governance matters.
Organon & Co. Proxy statement: Proxy filing
Organon & Co. filed a proxy statement on June 11, 2026, providing details for shareholder voting and corporate governance matters.
Organon wins US approval to widen use of arthritis biosimilar drug
Organon said on Wednesday the U.S. Food and Drug Administration has approved the expanded use of its arthritis drug, a biosimilar to Roche's Actemra, to treat a life‑threatening immune reaction in s...
Organon announces U.S. FDA approval pf sBLA for Tofidence injection
Organon (OGN) announced the US Food and Drug Administratio, FDA, approval of the supplemental Biologics License Application, sBLA, for Tofidence injection, for intravenous use, a biosimilar to Actemra...
Organon & Co. Transcript: AGM 2026
The virtual meeting established a quorum and saw all board and executive proposals approved, including director elections, executive compensation, and the amended Incentive Stock Plan. Final voting results will be filed with the SEC, and shareholder questions will be addressed online.
SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Organon & Co. (OGN)
Bala Cynwyd, Pennsylvania--(Newsfile Corp. - June 2, 2026) - Law office of Brodsky & Smith announces that it is investigating potential claims against the Board of Directors of Organon & Co. ("Organon...
Organon & Co. Proxy statement: Proxy filing
Organon & Co. filed a proxy statement on June 1, 2026, providing details for shareholder voting and corporate governance matters.
Hanmi Pharmaceutical Partners with Organon to Export Combination Therapies to Southeast Asia
Shin Hae-gon (right), Head of Overseas Sales at Hanmi Pharmaceutical, and Andreas Daugaard Jørgensen (left), Managing Director, Organon Asia Pacific Cluster, met at Organon's Malaysia office to discus...
Organon to present new research at ISPOR 2026
Organon (OGN) will present data across women’s health, biosimilars, dermatology, and neurology at ISPOR 2026, the leading global scientific conference hosted by the International Society for Pharmacoe...
Organon to Present New Research on Access and Value at ISPOR 2026
JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon to present 8 abstracts on affordability, access and adoption across women's health, biosimilar and general medicines portfolio at ISPOR 2026.
Organon & Co. Earnings release: Q1 2026
Organon & Co. released its Q1 2026 earnings on May 7, 2026, summarizing the period's financial results.
Organon & Co. Quarterly report: Q1 2026
Organon & Co. has published its Q1 2026 quarterly earnings report on May 7, 2026.
Organon will not provide financial guidance due to pending merger
In light of the pending merger, Organon (OGN) will not be providing financial guidance or hosting quarterly earnings calls.
Organon & Co. Proxy statement: Proxy filing
Organon & Co. filed a proxy statement on April 30, 2026, providing details for shareholder voting and corporate governance matters.
Organon & Co. Proxy statement: Proxy filing
Organon & Co. filed a proxy statement on April 30, 2026, providing details for shareholder voting and corporate governance matters.
Organon Reports Results for the First Quarter Ended March 31, 2026
JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon (NYSE: OGN) today announced its results for the first quarter ended March 31, 2026. First Quarter 2026 Revenue in $ millions Q1 2026 Q1 2025 VPY VPY...
Organon cancels Q1 earnings call
Organon (OGN) canceled its first quarter 2026 earnings conference call previously scheduled for May 7, 2026. The cancellation is the result of the company’s April 26, 2026 announcement that it…
Organon Cancels First Quarter Earnings Call
JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon (NYSE: OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, announced today that it has ...
Organon gets European Commission marketing authorization for Poherdy
Shanghai Henlius Biotech and Organon (OGN) announced the European Commission has granted marketing authorization for Poherdy 420 mg/14 mL injection for intravenous use. In 2022, Henlius entered into a...
Organon moved to No Rating at BofA
BofA moved to No Rating on Organon (OGN) after the company announced that it has agreed to be acquired by Sun Pharma for $14 per share in cash. The Sun…
Organon downgraded to Neutral from Outperform at BNP Paribas
BNP Paribas downgraded Organon (OGN) to Neutral from Outperform with a $14 price target after the company entered into an agreement under which Sun Pharma will acquire all outstanding shares…